The invention provides novel peptides (e.g., linkers) and polypeptide compositions comprising the linkers (e.g., fusion proteins) and methods of using the polypeptide compositions. Peptides (e.g., linkers) are useful as tags and for engineering fusion proteins (e.g., antigen binding molecules, scFv). Polypeptide linkers described herein facilitate flexibility of linked peptides allowing for proper folding, conformation and reduced immunogenicity.

Provided herein are biofilm inhibitors obtained from marine microbial derived natural product extracts from Streptomyces gandocaensis, resulting in biofilm inhibitors, cahuitamycins. Also provided are mutant S. gandocaensis, methods of inhibiting biofilm formation, methods of producing, or increasing the production of, cahuitamycins, methods for synthesizing cahuitamycins, and methods of purifying cahuitamycins.

The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.

##STR00001##

The peptides of the invention are of formula (I) or (IV). The peptides of the invention are useful in the treatment of cancer.

##STR00001##

A pH-responsive fusion peptide according to the present disclosure, containing a cell-penetrating peptide exhibiting a positive charge, which contains 2-15 arginine residues, and a -sheet-forming segment, experiences structural change depending on pH change. Due to the structural change, the anti-prion activity and cytotoxicity of the fusion peptide can be controlled as desired.

This invention relates to A-crystallin protein modulating compounds (e.g., phosphomimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment and prevention of conditions involving neurodegeneration and neuroinflammation.

This invention relates to A-crystallin protein modulating compounds (e.g., phosphomimetic peptides), compositions comprising such modulating compounds, and their use as therapeutics for the treatment and prevention of conditions involving neurodegeneration and neuroinflammation.

A purified and isolated peptide comprises an amino acid sequence of SEQ ID NOs: 1 to 8. A method is also provided for preventing interaction, e.g. binding, of EN1 with EPRS in a cell by introducing, into the cell, a peptide having a sequence of SEQ ID NOs: 1 to 8, which results in the peptide interacting with EPRS thereby preventing an interaction of EPRS with EN1. Apoptosis can be induced in a cell expressing either or both of EN1 and EN2, by introducing into the cell, a peptide of SEQ ID NOs: 1 to 8.

The present invention provides a method of generating a population of tumour-infiltrating T cells, said method comprising administering to a subject a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and then collecting a cellular sample from a tumour within said subject and separating T cells therefrom. The present invention further provides a method of generating a population of tumour-infiltrating T cells, said method comprising separating T cells from a cellular tumour sample taken from a subject treated with a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and optionally culturing said T cells. The present invention also provides the tumour-infiltrating T cells described above for use in treating tumour cells or preventing or reducing the growth, establishment, spread, or metastasis of a tumour.

The present invention provides a method of generating a population of tumour-infiltrating T cells, said method comprising administering to a subject a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and then collecting a cellular sample from a tumour within said subject and separating T cells therefrom. The present invention further provides a method of generating a population of tumour-infiltrating T cells, said method comprising separating T cells from a cellular tumour sample taken from a subject treated with a positively charged amphipathic amino acid derivative, peptide or peptidomimetic which is able to lyse tumour cell membranes and optionally culturing said T cells. The present invention also provides the tumour-infiltrating T cells described above for use in treating tumour cells or preventing or reducing the growth, establishment, spread, or metastasis of a tumour.